Health care of Kyrgyzstan
Zdravoohraneniye Kyrgyzstana

ISSN 1694-8068 (Print)

ISSN 1694-805X (Online)

Adverse events to drugs in the treatment of tuberculosis in Kyrgyz Republic

Adverse events to drugs in the treatment of tuberculosis in Kyrgyz Republic
Полный текст Full text Толук текст  

Abstract

Adverse reactions to drugs are a serious public health problem, which entails economic consequences: lengthening the length of the patient's stay in the hospital, the need to individualize treatment regimens with the inclusion of expensive reserve drugs, additional drugs and drugs to stop adverse reactions. The most problematic issue in the treatment of tuberculosis is inadequate adherence to treatment, due to its duration, complexity and associated adverse events, leads to the choice of a much more difficult and expensive treatment for multidrug-resistant tuberculosis. Inadequate treatment adherence occurs despite extensive global efforts by the World Health Organization, ministries of health and others to implement a highly labor-intensive TB treatment program that includes direct observation of treatment by public health workers. Treatment of tuberculosis involves the simultaneous and long-term use of four to eight drugs, each of which has a wide range of possible adverse effects. Most anti-TB drugs are well known and have been studied in clinical trials. However, individual signs and symptoms of adverse events, such as skin rashes, abdominal pain, jaundice, shock, visual impairment, hearing impairment, can cause severe consequences for patients stopping taking drugs, reducing the quality of life and complicating daily activities. The frequency of occurrence of adverse reactions to drugs in patients with tuberculosis was studied on the basis of received message cards / yellow cards for 2020-2021. in the Kyrgyz Republic.

About the authors

Осмонбеков Мирбек Доолотович, клинический фармаколог, отдел информатики и эпидемиологии Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Сагындыкова Саадат Орозбековна, координатор по лекарственному обеспечению, отдел информатики и эпидемиологии Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Кушубаков Данил Амантурович, врач фтизиортопед, отделения костной хирургии Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика,
Тункатарова Жазгуль Кемелбековна, координатор по лекарственному обеспечению, отдел информатики и эпидемиологии Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Сулайманова Меркинай Исаевна, к.м.н., специалист по лекарственному менеджменту Проекта USAID "Вылечить туберкулез", Бишкек, Кыргызская Республика

Osmonbekov Mirbek Doolotovich, Clinical Pharmacologist, Department of Informatics and Epidemiology, National Center for Phthisiology, Ministry of Health, Bishkek, Kyrgyz Republic
Sagyndykova Saadat Orozbekovna, Drug Supply Coordinator, Department of Informatics and Epidemiology, National Center for Phthisiology, Ministry of Health, Bishkek, Kyrgyz Republic
Kushubakov Danil Amanturovich, phthisiortopedin, Department of Bone Surgery, National Phthisiology Center, Ministry of Health, Bishkek, Kyrgyz Republic,
Tunkatarova Zhazgul Kemelbekovna, Drug Supply Coordinator, Department of Informatics and Epidemiology, National Center for Phthisiology, Ministry of Health, Bishkek, Kyrgyz Republic
Sulaymanova Merkinay Isaevna, Ph.D., Drug Management Specialist, USAID Cure Tuberculosis Project, Bishkek, Kyrgyz Republic

Осмонбеков Мирбек Доолотович, клиникалык фармаколог Улуттук фтизиатрия борборунун, информатика жана эпидемиология бөлүмү,Бишкек  Кыргыз Республикасы 

Сагындыкова Саадат Орозобековна, дары менен камсыздоо координатору Улуттук фтизиатрия борбору, информатика жана эпидемиология бөлүмү, Бишкек  Кыргыз Республикасы 

Кушубаков Данил Амантурович, Фтизиортопед дарыгери Улуттук фтизиатрия борбору, сөөк хирургия бөлүмү, Бишкек  Кыргыз Республикасы 

Тункатарова Жазгуль Кемелбековна, дары менен камсыздоо координатору Улуттук фтизиатрия борбору, информатика жана эпидемиология бөлүмү, Бишкек  Кыргыз Республикасы 

Сулайманова Меркинай Исаевна, медицина илимдеринин кандидаты, дары боюнча башкаруу боюнча адиси

USAID “Кургак учукту айыктыруу” долбоору, Бишкек  Кыргыз Республикасы 

References

1. World Health Organization. WHO report on the global elimination of tuberculosis 2020. Geneva: WHO; 2020.
2. Practical guide to pharmacovigilance of anti-TB drugs, Improving the safety of TB patients, WHO, 2012
3. Daphne E. Smith Marsh, PharmD, BC-ADM, CDCES, University of Illinois at Chicago College of Pharmacy 04. 2021
4. Pirmohamed M. et al. // British Medical Journal 329:15-19. 2004.
5. Patel KJ et al BMC Clinical Pharmacology volume 7, Article: 8, 2007.
6. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation WHO/HTM/TB/2015.28) [Internet] Geneva, World Health Organization; 2015.
7. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.04) [Internet]. Geneva, WHO. 2016.
8. WHO library cataloguing-in-publication data global tuberculosis report 2015. Geneva: World Health Organization; 2015.
9. Chimeh RA, Gafar F,Pradipta IS, Akkerman CW, Hak E, Alffenaar JC,et al. Directly Observed Therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;29(5)
10. Borua CG, Shimelsb T, Bilal AI. Factors contributing to non-adherence with treatment among TB patients in Sodo Woreda,Gurage zone, southern Ethiopia: a qualitative study. J Infect Public Health. 2017;10(5).
11. Moonan PK, Quitugua TN, Pogoda JM, Woo G, Drewyer G, Sahbazian B, et al. Does directly observed therapy (DOT) reducedrug resistant tuberculosis? BMC Public Health 2011;
12. Gebremariam MK, Bjune G, Frich JC. Barriers and facilitators of adherence toTB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;
13. Challenges in tuberculosis drug research and development. Ann M Ginsberg & Melvin Spigelman. Nature Medicine volume 13, p.290–294 (2007)

1. World Health Organization. WHO report on the global elimination of tuberculosis 2020. Geneva: WHO; 2020.
2. Practical guide to pharmacovigilance of anti-TB drugs, Improving the safety of TB patients, WHO, 2012
3. Daphne E. Smith Marsh, PharmD, BC-ADM, CDCES, University of Illinois at Chicago College of Pharmacy 04. 2021
4. Pirmohamed M. et al. // British Medical Journal 329:15-19. 2004.
5. Patel KJ et al BMC Clinical Pharmacology volume 7, Article: 8, 2007.
6. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation WHO/HTM/TB/2015.28) [Internet] Geneva, World Health Organization; 2015.
7. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.04) [Internet]. Geneva, WHO. 2016.
8. WHO library cataloguing-in-publication data global tuberculosis report 2015. Geneva: World Health Organization; 2015.
9. Chimeh RA, Gafar F,Pradipta IS, Akkerman CW, Hak E, Alffenaar JC,et al. Directly Observed Therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;29(5)
10. Borua CG, Shimelsb T, Bilal AI. Factors contributing to non-adherence with treatment among TB patients in Sodo Woreda,Gurage zone, southern Ethiopia: a qualitative study. J Infect Public Health. 2017;10(5).
11. Moonan PK, Quitugua TN, Pogoda JM, Woo G, Drewyer G, Sahbazian B, et al. Does directly observed therapy (DOT) reducedrug resistant tuberculosis? BMC Public Health 2011;
12. Gebremariam MK, Bjune G, Frich JC. Barriers and facilitators of adherence toTB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;
13. Challenges in tuberculosis drug research and development. Ann M Ginsberg & Melvin Spigelman. Nature Medicine volume 13, p.290–294 (2007)

1. World Health Organization. WHO report on the global elimination of tuberculosis 2020. Geneva: WHO; 2020.
2. Practical guide to pharmacovigilance of anti-TB drugs, Improving the safety of TB patients, WHO, 2012
3. Daphne E. Smith Marsh, PharmD, BC-ADM, CDCES, University of Illinois at Chicago College of Pharmacy 04. 2021
4. Pirmohamed M. et al. // British Medical Journal 329:15-19. 2004.
5. Patel KJ et al BMC Clinical Pharmacology volume 7, Article: 8, 2007.
6. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation WHO/HTM/TB/2015.28) [Internet] Geneva, World Health Organization; 2015.
7. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.04) [Internet]. Geneva, WHO. 2016.
8. WHO library cataloguing-in-publication data global tuberculosis report 2015. Geneva: World Health Organization; 2015.
9. Chimeh RA, Gafar F,Pradipta IS, Akkerman CW, Hak E, Alffenaar JC,et al. Directly Observed Therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;29(5)
10. Borua CG, Shimelsb T, Bilal AI. Factors contributing to non-adherence with treatment among TB patients in Sodo Woreda,Gurage zone, southern Ethiopia: a qualitative study. J Infect Public Health. 2017;10(5).
11. Moonan PK, Quitugua TN, Pogoda JM, Woo G, Drewyer G, Sahbazian B, et al. Does directly observed therapy (DOT) reducedrug resistant tuberculosis? BMC Public Health 2011;
12. Gebremariam MK, Bjune G, Frich JC. Barriers and facilitators of adherence toTB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;
13. Challenges in tuberculosis drug research and development. Ann M Ginsberg & Melvin Spigelman. Nature Medicine volume 13, p.290–294 (2007)

Для цитирования

Осмонбеков М.Д., Сагындыкова С.О., Кушубаков Д.А.,Тункатарова Ж.К., Сулайманова М.И. Нежелательные реакции на лекарственные средства при лечении туберкулеза в Кыргызской Республике. Здравоохранение Кыргызстана 2022, № 2,с. 97-102. https://dx.doi.org/10.51350/zdravkg2022621397

For citation

Osmonbekov M.D, Sagyndykova S.O, Kushubakov D.A,Tunkatarova J.K, Sulaimanova M.I. Adverse drug reactions
in the treatment of tuberculosis in the Kyrgyz Republic. Health care of Kyrgyzstan 2022,No.2, pp. 97-102.  https://dx.doi.org/10.51350/zdravkg2022621397

Цитата үчүн

Осмонбеков М.Д., Сагындыкова С.О., Кушубаков Д.А.,Тункатарова Ж.К., Сулайманова М.И. Кыргыз Республикасында кургак учукту дарылоодо дарылардын терстаасирлери. Кыргызстандын саламаттык сактоо 2022, no 2, б. 97-102. https://dx.doi.org/10.51350/zdravkg2022621397

Authors Osmonbekov M.D., Sagyndykova S.O., Kushubakov D.A., Tunkatarova J.K., Sulaimanova M.I.
Link doi.org https://doi.org/10.51350/zdravkg2022621397
Pages 97-102
Keywords adverse reactions, report cards / yellow cards, tuberculosis, anti-tuberculosis drugs, infectivity, suspect drugs, preventability
Russian
Об авторах

Осмонбеков Мирбек Доолотович, клинический фармаколог, отдел информатики и эпидемиологии Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Сагындыкова Саадат Орозбековна, координатор по лекарственному обеспечению, отдел информатики и эпидемиологии Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Кушубаков Данил Амантурович, врач фтизиортопед, отделения костной хирургии Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика,
Тункатарова Жазгуль Кемелбековна, координатор по лекарственному обеспечению, отдел информатики и эпидемиологии Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Сулайманова Меркинай Исаевна, к.м.н., специалист по лекарственному менеджменту Проекта USAID "Вылечить туберкулез", Бишкек, Кыргызская Республика

Полный текст

PDF (RUS)

Список литературы

1. World Health Organization. WHO report on the global elimination of tuberculosis 2020. Geneva: WHO; 2020.
2. Practical guide to pharmacovigilance of anti-TB drugs, Improving the safety of TB patients, WHO, 2012
3. Daphne E. Smith Marsh, PharmD, BC-ADM, CDCES, University of Illinois at Chicago College of Pharmacy 04. 2021
4. Pirmohamed M. et al. // British Medical Journal 329:15-19. 2004.
5. Patel KJ et al BMC Clinical Pharmacology volume 7, Article: 8, 2007.
6. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation WHO/HTM/TB/2015.28) [Internet] Geneva, World Health Organization; 2015.
7. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.04) [Internet]. Geneva, WHO. 2016.
8. WHO library cataloguing-in-publication data global tuberculosis report 2015. Geneva: World Health Organization; 2015.
9. Chimeh RA, Gafar F,Pradipta IS, Akkerman CW, Hak E, Alffenaar JC,et al. Directly Observed Therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;29(5)
10. Borua CG, Shimelsb T, Bilal AI. Factors contributing to non-adherence with treatment among TB patients in Sodo Woreda,Gurage zone, southern Ethiopia: a qualitative study. J Infect Public Health. 2017;10(5).
11. Moonan PK, Quitugua TN, Pogoda JM, Woo G, Drewyer G, Sahbazian B, et al. Does directly observed therapy (DOT) reducedrug resistant tuberculosis? BMC Public Health 2011;
12. Gebremariam MK, Bjune G, Frich JC. Barriers and facilitators of adherence toTB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;
13. Challenges in tuberculosis drug research and development. Ann M Ginsberg & Melvin Spigelman. Nature Medicine volume 13, p.290–294 (2007)

Для цитирования

Осмонбеков М.Д., Сагындыкова С.О., Кушубаков Д.А.,Тункатарова Ж.К., Сулайманова М.И. Нежелательные реакции на лекарственные средства при лечении туберкулеза в Кыргызской Республике. Здравоохранение Кыргызстана 2022, № 2,с. 97-102. https://dx.doi.org/10.51350/zdravkg2022621397

English
About authors

Osmonbekov Mirbek Doolotovich, Clinical Pharmacologist, Department of Informatics and Epidemiology, National Center for Phthisiology, Ministry of Health, Bishkek, Kyrgyz Republic
Sagyndykova Saadat Orozbekovna, Drug Supply Coordinator, Department of Informatics and Epidemiology, National Center for Phthisiology, Ministry of Health, Bishkek, Kyrgyz Republic
Kushubakov Danil Amanturovich, phthisiortopedin, Department of Bone Surgery, National Phthisiology Center, Ministry of Health, Bishkek, Kyrgyz Republic,
Tunkatarova Zhazgul Kemelbekovna, Drug Supply Coordinator, Department of Informatics and Epidemiology, National Center for Phthisiology, Ministry of Health, Bishkek, Kyrgyz Republic
Sulaymanova Merkinay Isaevna, Ph.D., Drug Management Specialist, USAID Cure Tuberculosis Project, Bishkek, Kyrgyz Republic

Full text

PDF (RUS)

References

1. World Health Organization. WHO report on the global elimination of tuberculosis 2020. Geneva: WHO; 2020.
2. Practical guide to pharmacovigilance of anti-TB drugs, Improving the safety of TB patients, WHO, 2012
3. Daphne E. Smith Marsh, PharmD, BC-ADM, CDCES, University of Illinois at Chicago College of Pharmacy 04. 2021
4. Pirmohamed M. et al. // British Medical Journal 329:15-19. 2004.
5. Patel KJ et al BMC Clinical Pharmacology volume 7, Article: 8, 2007.
6. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation WHO/HTM/TB/2015.28) [Internet] Geneva, World Health Organization; 2015.
7. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.04) [Internet]. Geneva, WHO. 2016.
8. WHO library cataloguing-in-publication data global tuberculosis report 2015. Geneva: World Health Organization; 2015.
9. Chimeh RA, Gafar F,Pradipta IS, Akkerman CW, Hak E, Alffenaar JC,et al. Directly Observed Therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;29(5)
10. Borua CG, Shimelsb T, Bilal AI. Factors contributing to non-adherence with treatment among TB patients in Sodo Woreda,Gurage zone, southern Ethiopia: a qualitative study. J Infect Public Health. 2017;10(5).
11. Moonan PK, Quitugua TN, Pogoda JM, Woo G, Drewyer G, Sahbazian B, et al. Does directly observed therapy (DOT) reducedrug resistant tuberculosis? BMC Public Health 2011;
12. Gebremariam MK, Bjune G, Frich JC. Barriers and facilitators of adherence toTB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;
13. Challenges in tuberculosis drug research and development. Ann M Ginsberg & Melvin Spigelman. Nature Medicine volume 13, p.290–294 (2007)

For citation

Osmonbekov M.D, Sagyndykova S.O, Kushubakov D.A,Tunkatarova J.K, Sulaimanova M.I. Adverse drug reactions
in the treatment of tuberculosis in the Kyrgyz Republic. Health care of Kyrgyzstan 2022,No.2, pp. 97-102.  https://dx.doi.org/10.51350/zdravkg2022621397

Kyrgyz
Авторлор жөнүндө

Осмонбеков Мирбек Доолотович, клиникалык фармаколог Улуттук фтизиатрия борборунун, информатика жана эпидемиология бөлүмү,Бишкек  Кыргыз Республикасы 

Сагындыкова Саадат Орозобековна, дары менен камсыздоо координатору Улуттук фтизиатрия борбору, информатика жана эпидемиология бөлүмү, Бишкек  Кыргыз Республикасы 

Кушубаков Данил Амантурович, Фтизиортопед дарыгери Улуттук фтизиатрия борбору, сөөк хирургия бөлүмү, Бишкек  Кыргыз Республикасы 

Тункатарова Жазгуль Кемелбековна, дары менен камсыздоо координатору Улуттук фтизиатрия борбору, информатика жана эпидемиология бөлүмү, Бишкек  Кыргыз Республикасы 

Сулайманова Меркинай Исаевна, медицина илимдеринин кандидаты, дары боюнча башкаруу боюнча адиси

USAID “Кургак учукту айыктыруу” долбоору, Бишкек  Кыргыз Республикасы 

Толук текст

PDF (RUS)

Шилтемелер

1. World Health Organization. WHO report on the global elimination of tuberculosis 2020. Geneva: WHO; 2020.
2. Practical guide to pharmacovigilance of anti-TB drugs, Improving the safety of TB patients, WHO, 2012
3. Daphne E. Smith Marsh, PharmD, BC-ADM, CDCES, University of Illinois at Chicago College of Pharmacy 04. 2021
4. Pirmohamed M. et al. // British Medical Journal 329:15-19. 2004.
5. Patel KJ et al BMC Clinical Pharmacology volume 7, Article: 8, 2007.
6. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation WHO/HTM/TB/2015.28) [Internet] Geneva, World Health Organization; 2015.
7. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.04) [Internet]. Geneva, WHO. 2016.
8. WHO library cataloguing-in-publication data global tuberculosis report 2015. Geneva: World Health Organization; 2015.
9. Chimeh RA, Gafar F,Pradipta IS, Akkerman CW, Hak E, Alffenaar JC,et al. Directly Observed Therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;29(5)
10. Borua CG, Shimelsb T, Bilal AI. Factors contributing to non-adherence with treatment among TB patients in Sodo Woreda,Gurage zone, southern Ethiopia: a qualitative study. J Infect Public Health. 2017;10(5).
11. Moonan PK, Quitugua TN, Pogoda JM, Woo G, Drewyer G, Sahbazian B, et al. Does directly observed therapy (DOT) reducedrug resistant tuberculosis? BMC Public Health 2011;
12. Gebremariam MK, Bjune G, Frich JC. Barriers and facilitators of adherence toTB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;
13. Challenges in tuberculosis drug research and development. Ann M Ginsberg & Melvin Spigelman. Nature Medicine volume 13, p.290–294 (2007)

Цитата үчүн

Осмонбеков М.Д., Сагындыкова С.О., Кушубаков Д.А.,Тункатарова Ж.К., Сулайманова М.И. Кыргыз Республикасында кургак учукту дарылоодо дарылардын терстаасирлери. Кыргызстандын саламаттык сактоо 2022, no 2, б. 97-102. https://dx.doi.org/10.51350/zdravkg2022621397

Views: 3594
Copyright MAXXmarketing GmbH
JoomShopping Download & Support